Tarsus Pharmaceuticals (NASDAQ: TARS) revenue
Tarsus Pharmaceuticals reported revenue of $451.4m for fiscal 2025, 146.7% more than in fiscal 2024 ($183.0m).
Tarsus Pharmaceuticals has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record. The biggest drop was in fiscal 2022, −54.7%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $451.4m | +146.7% | −$71.0m | −15.7% |
| 2024 | $183.0m | +948.6% | −$120.6m | −65.9% |
| 2023 | $17.4m | −32.4% | −$143.2m | −820.5% |
| 2022 | $25.8m | −54.7% | −$62.7m | −242.9% |
| 2021 | $57.0m | — | −$12.2m | −21.3% |
| 2020 | $0.0m | — | −$27.0m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Tarsus Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Tarsus Pharmaceuticals ranks 198th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Tarsus Pharmaceuticals, 146.7%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 196th | Phreesia | $480.6m | 14.5% |
| 197th | Zai Lab | $460.2m | 15.3% |
| 198th | Tarsus Pharmaceuticals | $451.4m | 146.7% |
| 199th | Artivion | $441.3m | 13.6% |
| 200th | GeneDx | $427.5m | 40.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Tarsus Pharmaceuticals
- How much revenue did Tarsus Pharmaceuticals make in fiscal 2025?
- Tarsus Pharmaceuticals reported revenue of $451.4m for fiscal 2025, compared with $183.0m in fiscal 2024.
- What was the best year for revenue at Tarsus Pharmaceuticals?
- Of its last 6 fiscal years, fiscal 2025, with $451.4m.
- Where does Tarsus Pharmaceuticals rank in its sector by revenue?
- It ranks 198th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Tarsus Pharmaceuticals come from?
- From the annual report (Form 10-K) that Tarsus Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Tarsus Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Tarsus Pharmaceuticals: the Tarsus Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.